BACKGROUND: In the laboratory evaluation of suspected paracetamol poisoning, a non-invasive sample type that avoids venepuncture would be an attractive alternative to plasma, particularly in the paediatric setting. Salivary paracetamol measurement has not previously been evaluated in the published medical literature in the setting of deliberate self-poisoning (DSP). METHODS: In-house validation experiments (recovery, stability and lower limit-of-detection) were performed on pooled saliva samples using a Roche Acetaminophen assay on a Roche/Hitachi 917 analyser. A clinical study of comparison of paired saliva and plasma samples was also conducted involving adult patients presenting with DSP of paracetamol, the results of which were published previously. RESULTS: The validation experiments using pooled saliva samples showed: (i) mean recovery (paracetamol concentration 37.5-525 mg/L) 100.01% (+/-0.02 SD); (ii) precision of repeated assay over 24-h period CV <4%; (iii) lower limit-of-detection 0.9 mg/L. The clinical study of 21 patients with mean plasma paracetamol concentration of 48 mg/L (range 0-130) and mean saliva concentration 62 mg/L (range 0-183) showed good correlation between saliva and plasma concentrations (r(2) = 0.91). CONCLUSIONS: The Roche Hitachi 917 Acetaminophen assay is suitable for the measurement of paracetamol in saliva. Further studies comparing plasma and saliva samples from patients with DSP and plasma paracetamol concentrations in the hepatotoxic range are warranted. If salivary samples are suitable for risk-stratifying patients with paracetamol DSP, venepuncture may be avoided, which would be attractive, especially in the paediatric setting.
BACKGROUND: In the laboratory evaluation of suspected paracetamolpoisoning, a non-invasive sample type that avoids venepuncture would be an attractive alternative to plasma, particularly in the paediatric setting. Salivary paracetamol measurement has not previously been evaluated in the published medical literature in the setting of deliberate self-poisoning (DSP). METHODS: In-house validation experiments (recovery, stability and lower limit-of-detection) were performed on pooled saliva samples using a Roche Acetaminophen assay on a Roche/Hitachi 917 analyser. A clinical study of comparison of paired saliva and plasma samples was also conducted involving adult patients presenting with DSP of paracetamol, the results of which were published previously. RESULTS: The validation experiments using pooled saliva samples showed: (i) mean recovery (paracetamol concentration 37.5-525 mg/L) 100.01% (+/-0.02 SD); (ii) precision of repeated assay over 24-h period CV <4%; (iii) lower limit-of-detection 0.9 mg/L. The clinical study of 21 patients with mean plasma paracetamol concentration of 48 mg/L (range 0-130) and mean saliva concentration 62 mg/L (range 0-183) showed good correlation between saliva and plasma concentrations (r(2) = 0.91). CONCLUSIONS: The Roche Hitachi 917 Acetaminophen assay is suitable for the measurement of paracetamol in saliva. Further studies comparing plasma and saliva samples from patients with DSP and plasma paracetamol concentrations in the hepatotoxic range are warranted. If salivary samples are suitable for risk-stratifying patients with paracetamol DSP, venepuncture may be avoided, which would be attractive, especially in the paediatric setting.
Authors: Jessamine H Soderstrom; Daniel M Fatovich; Christine Mandelt; Sam Vasikaran; David L McCoubrie; Frank F Daly; Sally A Burrows Journal: Br J Clin Pharmacol Date: 2012-07 Impact factor: 4.335